Company / Revenue per Share
Myriad Genetics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$10.15
FY2025
5-year range
$9.23 / $10.47
FY2021-FY2025
Trend
-3.0%
vs FY2024
Sector context
#45 of 154
Health Care
What the data says
At $10.15, Myriad Genetics, Inc.'s revenue per share ranks #45 of 154 in the Health Care sector. Revenue per Share has fluctuated over the past 10 years, ranging from $9.23 in FY2022 to $10.79 in FY2018.
Based on SEC 10-K filings.
10.15 in FY2025 with a 5-year CAGR of +1.7%.
Remained stable around $10.15 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +3.2%
- 5-Year CAGR
- +1.7%
- 10-Year CAGR
- -
Sector benchmark
#45 of 154 in Health CareTop 29% of 154This company $10.15 Sector average $10.35
▼
-1.9% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 3.0% year-over-year.
- Ranks #45 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2018.
- Lowest revenue per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.15 | -3.0% |
| FY2024 | $10.47 | +4.8% |
| FY2023 | $9.99 | +8.2% |
| FY2022 | $9.23 | -5.6% |
| FY2021 | $9.78 | +4.8% |
| FY2020 | $9.34 | -11.5% |
| FY2019 | $10.55 | -2.3% |
| FY2018 | $10.79 | +2.8% |
| FY2017 | $10.50 | +12.2% |
| FY2016 | $9.35 | +6.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026